Last reviewed · How we verify

Allergy & Asthma Medical Group & Research Center — Portfolio Competitive Intelligence Brief

Allergy & Asthma Medical Group & Research Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
fluticasone/salmeterol DISKUS 250/50 fluticasone/salmeterol DISKUS 250/50 marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergy and Asthma Center of El Paso · 1 shared drug class
  2. AstraZeneca · 1 shared drug class
  3. Chiesi Farmaceutici S.p.A. · 1 shared drug class
  4. Far Eastern Memorial Hospital · 1 shared drug class
  5. Gelb, Arthur F., M.D. · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Istituto per la Ricerca e l'Innovazione Biomedica · 1 shared drug class
  8. AO GENERIUM · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Allergy & Asthma Medical Group & Research Center:

Cite this brief

Drug Landscape (2026). Allergy & Asthma Medical Group & Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allergy-asthma-medical-group-research-center. Accessed 2026-05-17.

Related